Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever.

Seher SenerVeysel CamEzgi Deniz BatuMuserref Kasap CuceogluZeynep BalikEmil AliyevYagmur BayindirOzge BasaranYelda BilginerSeher Sener

Published in: Rheumatology (Oxford, England) (2023)

This is the largest study in the literature suggesting a protocol for discontinuing canakinumab in pediatric FMF patients. It was possible to discontinue canakinumab successfully in more than half of the patients in 18 months. Thus, we suggest that this protocol can be used in pediatric FMF patients.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
systematic review
patient reported outcomes